Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 1
1980 4
1981 4
1982 2
1983 4
1984 4
1985 5
1986 7
1987 7
1988 8
1989 10
1990 7
1991 3
1992 3
1993 3
1994 4
1995 3
1996 5
1997 4
1998 5
1999 2
2000 2
2001 1
2002 7
2003 3
2004 4
2005 5
2006 6
2007 8
2008 4
2009 6
2010 8
2011 7
2012 5
2013 11
2014 5
2015 4
2016 3
2017 6
2018 4
2019 4
2020 11
2021 4
2022 6
2023 6
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

218 results

Results by year

Filters applied: . Clear all
Page 1
Soluble immune checkpoint factors reflect exhaustion of antitumor immunity and response to PD-1 blockade.
Hayashi H, Chamoto K, Hatae R, Kurosaki T, Togashi Y, Fukuoka K, Goto M, Chiba Y, Tomida S, Ota T, Haratani K, Takahama T, Tanizaki J, Yoshida T, Iwasa T, Tanaka K, Takeda M, Hirano T, Yoshida H, Ozasa H, Sakamori Y, Sakai K, Higuchi K, Uga H, Suminaka C, Hirai T, Nishio K, Nakagawa K, Honjo T. Hayashi H, et al. Among authors: ozasa h. J Clin Invest. 2024 Apr 1;134(7):e168318. doi: 10.1172/JCI168318. J Clin Invest. 2024. PMID: 38557498 Free PMC article.
Combination bezafibrate and nivolumab treatment of patients with advanced non-small cell lung cancer.
Tanaka K, Chamoto K, Saeki S, Hatae R, Ikematsu Y, Sakai K, Ando N, Sonomura K, Kojima S, Taketsuna M, Kim YH, Yoshida H, Ozasa H, Sakamori Y, Hirano T, Matsuda F, Hirai T, Nishio K, Sakagami T, Fukushima M, Nakanishi Y, Honjo T, Okamoto I. Tanaka K, et al. Among authors: ozasa h. Sci Transl Med. 2022 Dec 14;14(675):eabq0021. doi: 10.1126/scitranslmed.abq0021. Epub 2022 Dec 14. Sci Transl Med. 2022. PMID: 36516270
Adaptive resistance to lorlatinib via EGFR signaling in ALK-rearranged lung cancer.
Katayama Y, Yamada T, Tanimura K, Tokuda S, Morimoto K, Hirai S, Matsui Y, Nakamura R, Ishida M, Kawachi H, Yoneda K, Hosoya K, Tsuji T, Ozasa H, Yoshimura A, Iwasaku M, Kim YH, Horinaka M, Sakai T, Utsumi T, Shiotsu S, Takeda T, Katayama R, Takayama K. Katayama Y, et al. Among authors: ozasa h. NPJ Precis Oncol. 2023 Jan 26;7(1):12. doi: 10.1038/s41698-023-00350-7. NPJ Precis Oncol. 2023. PMID: 36702855 Free PMC article.
Combination Therapy with EGFR Tyrosine Kinase Inhibitors and TEAD Inhibitor Increases Tumor Suppression Effects in EGFR Mutation-positive Lung Cancer.
Ogimoto T, Ozasa H, Tsuji T, Funazo T, Yamazoe M, Hashimoto K, Yoshida H, Hosoya K, Ajimizu H, Nomizo T, Yoshida H, Hamaji M, Menju T, Yoshizawa A, Date H, Hirai T. Ogimoto T, et al. Among authors: ozasa h. Mol Cancer Ther. 2024 Apr 2;23(4):564-576. doi: 10.1158/1535-7163.MCT-23-0371. Mol Cancer Ther. 2024. PMID: 38052760
Paratracheal Middle Mediastinal Thymic Carcinomas.
Nakanobo R, Hamaji M, Ohsumi A, Koyasu S, Yoshida H, Ozasa H, Isowa M, Nakajima N, Yoshizawa A, Date H. Nakanobo R, et al. Among authors: ozasa h. Ann Thorac Surg. 2020 Jul;110(1):e39-e41. doi: 10.1016/j.athoracsur.2019.11.014. Epub 2019 Dec 31. Ann Thorac Surg. 2020. PMID: 31901463 Free article.
Yes-associated protein 1 mediates initial cell survival during lorlatinib treatment through AKT signaling in ROS1-rearranged lung cancer.
Yamazoe M, Ozasa H, Tsuji T, Funazo T, Yoshida H, Hashimoto K, Hosoya K, Ogimoto T, Ajimizu H, Yoshida H, Itotani R, Sakamori Y, Kuninaga K, Aoki W, Hirai T. Yamazoe M, et al. Among authors: ozasa h. Cancer Sci. 2023 Feb;114(2):546-560. doi: 10.1111/cas.15622. Epub 2022 Nov 23. Cancer Sci. 2023. PMID: 36285485 Free PMC article.
Recurrence patterns and progression-free survival after chemoradiotherapy with or without consolidation durvalumab for stage III non-small cell lung cancer.
Kishi N, Matsuo Y, Shintani T, Ogura M, Mitsuyoshi T, Araki N, Fujii K, Okumura S, Nakamatsu K, Kishi T, Atsuta T, Sakamoto T, Ohtsu S, Katagiri T, Narabayashi M, Fujishiro S, Iizuka Y, Ozasa H, Hirai T, Mizowaki T; Kyoto Radiation Oncology Study Group (KROSG). Kishi N, et al. Among authors: ozasa h. J Radiat Res. 2023 Jan 20;64(1):142-153. doi: 10.1093/jrr/rrac057. J Radiat Res. 2023. PMID: 36149029 Free PMC article.
PD-L1 Expression in Small Cell Lung Cancer.
Yasuda Y, Ozasa H, Kim YH. Yasuda Y, et al. Among authors: ozasa h. J Thorac Oncol. 2018 Mar;13(3):e40-e41. doi: 10.1016/j.jtho.2017.10.013. J Thorac Oncol. 2018. PMID: 29472058 Free article. No abstract available.
218 results